5 August 2021 Akston Biosciences Doses First Subjects in Phase II Clinical Trial of Second-Generation Protein Subunit COVID-19 Vaccine
21 July 2021 Akston Biosciences Announces Commercial Supply Agreement of Seppic’s Adjuvant to Formulate Akston Shelf-stable COVID-19 Vaccine at Global Scale
8 July 2021 Akston Biosciences Announces Positive Phase I Data for Second-Generation COVID-19 Vaccine Candidate
12 April 2021 Akston Biosciences Launches Phase I/II Clinical Trial of Second-Generation COVID-19 Vaccine
